Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats

Cardiovascular Research

Volumn 80, Issue 1, 2008, Pages 78-87

  Yu, Bu Chin ^a   Chang, Chen Kuei ^b   Ou, Horng Yih ^a   Cheng, Kai Chun ^a   Cheng, Juei Tang ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cardiomyopathy; Cell culture; Diabetes; Gene expression; Oxygen radicals

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ALPHA ACTININ; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; REACTIVE OXYGEN METABOLITE; STREPTOZOCIN; TIRON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CELL SIZE; CELL STRUCTURE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; HEART MUSCLE CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; MALE; NEWBORN; NONHUMAN; NORTHERN BLOTTING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; STREPTOZOCIN DIABETES; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CARDIOMYOPATHIES; CELL ENLARGEMENT; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCYTES, CARDIAC; PPAR DELTA; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES;

EID: 51749114921     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn172     Document Type: Article

References (49)

1. Fonarow GC, Srikanthan P. Diabetic cardiomyopathy. Endocrinol Metab Clin North Am 2006;35:575-599.
2. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 2006;98:596-605.
3. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006;291:H1489-H1506.
4. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115:3213-3223.
5. Wold LE, Ceylan-Isik AF, Ren J. Oxidative stress and stress signaling: menace of diabetic cardiomyopathy. Acta Pharmacol Sin 2005;26:908-917.
6. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001;1:181-193.
7. Fiordaliso F, Bianchi R, Staszewsky L, Cuccovillo I, Doni M, Laragione Tet al. Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 2004;37:959-968.
8. Ravingerová T, Barancík M, Strnisková M. Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 2003;247:127-138.
9. Sugden PH, Bogoyevitch MA. Intracellular signalling through protein kinases in the heart. Cardiovasc Res 1995;30:478-492.
10. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994;78:1027-1037.
11. Pulverer BJ, Kyriakis JM, Avruch J, Nikolakaki E, Woodgett JR. Phosphorylation of c-Jun mediated by MAP kinases. Nature 1991;353:670-674.
12. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347:645-650.
13. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 2001;142:4195-4202.
14. Cheng L, Ding G, Qin Q, Xiao Y, Woods D, Chen YE et al. Peroxisome proliferator-activated receptor delta activates fatty acid oxidation in cultured neonatal and adult cardiomyocytes. Biochem Biophys Res Commun 2004;313:277-286.
15. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 2004;10:1245-1250.
16. Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC et al. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res 2005;65:832-841.
17. Pesant M, Sueur S, Dutartre P, Tallandier M, Grimaldi PA, Rochette L et al. Peroxisome proliferator-activated receptor delta (PPARdelta) activation protects H9c2 cardiomyoblasts from oxidative stress-induced apoptosis. Cardiovasc Res 2006;69:440-449.
18. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006;116:590-597.
19. Mathur A, Hong Y, Kemp BK, Barrientos AA, Erusalimsky JD. Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes. Cardiovasc Res 2000;46:126-138.
20. Modesti A, Bertolozzi I, Gamberi T, Marchetta M, Lumachi C, Coppo M et al. Hyperglycemia activates JAK2 signaling pathway in human failing myocytes via angiotensin II-mediated oxidative stress. Diabetes 2005; 54:394-401.
21. Yue TL, Gu JL, Wang C, Reith AD, Lee JC, Mirabile RC et al. Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem 2000;275:37895-37901.
22. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002;51:1938-1948.
23. Huber SA. T cells expressing the gamma delta T cell receptor induce apoptosis in cardiac myocytes. Cardiovasc Res 2000;45:579-587.
24. Yamazaki T, Komuro I, Yazaki Y. Molecular mechanism of cardiac cellular hypertrophy by mechanical stress. J Mol Cell Cardiol 1995;27:133- 140.
25. Naitoh K, Ichikawa Y, Miura T, Nakamura Y, Miki T, Ikeda Y et al. MitoKATP channel activation suppresses gap junction permeability in the ischemic myocardium by an ERK-dependent mechanism. Cardiovasc Res 2006;70:374-383.
26. Zhai P, Gao S, Holle E, Yu X, Yatani A, Wagner T et al. Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases. J Biol Chem 2007;282:33181-33191.
27. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin Nl et al. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001;98:5306-5311.
28. Muscat GE, Dressel U. Cardiovascular disease and PPARdelta: targeting the risk factors. Curr Opin Investig Drugs 2005;6:887-894.
29. Jucker BM, Doe CP, Schnackenberg CG, Olzinski AR, Maniscalco K, Williams C et al. PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure. J Cardiovasc Pharmacol 2007;50:25-34.
30. Vadlamudi RV, Rodgers RL, McNeill JH. The effect of chronic alloxan- and streptozotocin-induced diabetes on isolated rat heart performance. Can J Physiol Pharmacol 1982;60:902-911.
31. Rodrigues B, Cam MC, McNeill JH. Metabolic disturbances in diabetic cardiomyopathy. Mol Cell Biochem 1998;180:53-57.
32. Billimoria FR, Katyare SS, Patel SP. Insulin status differentially affects energy transduction in cardiac mitochondria from male and female rats. Diabetes Obes Metab 2006;8:67-74.
33. Penpargkul S, Schaible T, Yipintsoi T, Scheuer J. The effect of diabetes on performance and metabolism of rat hearts. Circ Res 1980;47:911-921.
34. Litwin SE, Raya TE, Anderson PG, Daugherty S, Goldman S. Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle. J Clin Invest 1990;86:481-488.
35. Mihm MJ, Seifert JL, Coyle CM, Bauer JA. Diabetes related cardiomyopathy time dependent echocardiographic evaluation in an experimental rat model. Life Sci 2001;69:527-542.
36. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem 2004;261:187-191.
37. Liao Y, Takashima S, Zhao H, Asano Y, Shintani Y, Minamino Tet al. Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice. Cardiovasc Res 2006;70:107-116.
38. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001;108:1429-1437.
39. Zhang SL, To C, Chen X, Filep JG, Tang SS, Ingelfinger JR et al. Effect of renin-angiotensin system blockade on the expression of the angiotensinogen gene and induction of hypertrophy in rat kidney proximal tubular cells. Exp Nephrol 2001;9:109-117.
40. Fan YP, Weiss RH. Exogenous attenuation of p21(Waf1/Cip1) decreases mesangial cell hypertrophy as a result of hyperglycemia and IGF-1. J Am Soc Nephrol 2004;15:575-584.
41. Jonas JC, Laybutt DR, Steil GM, Trivedi N, Pertusa JG, Van de Casteele M et al. High glucose stimulates early response gene c-Myc expression in rat pancreatic beta cells. J Biol Chem 2001;276:35375-35381.
42. Laybutt DR, Kaneto H, Hasenkamp W, Grey S, Jonas JC, Sgroi DC et al. Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to beta-cell survival during chronic hyperglycemia. Diabetes 2002;51:413-423.
43. Babu GJ, Lalli MJ, Sussman MA, Sadoshima J, Periasamy M. Phosphorylation of elk-1 by MEK/ERK pathway is necessary for c-fos gene activation during cardiac myocyte hypertrophy. J Mol Cell Cardiol 2000;32:1447- 1457.
44. Wang L, Gout I, Proud CG. Cross-talk between the ERK and p70 S6 kinase (S6K) signaling pathways. MEK-dependent activation of S6K2 in cardiomyocytes. J Biol Chem 2001;276:32670-32677.
45. Ueyama T, Kawashima S, Sakoda T, Rikitake Y, Ishida T, Kawai M et al. Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy. J Mol Cell Cardiol 2000;32:947-960.
46. Clerk A, Bogoyevitch MA, Anderson MB, Sugden PH. Differential activation of protein kinase C isoforms by endothelin-1 and phenylephrine and subsequent stimulation of p42 and p44 mitogen-activated protein kinases in ventricular myocytes cultured from neonatal rat hearts. J Biol Chem 1994;269:32848-32857.
47. Sugden PH, Clerk A. 'Stress-responsive' mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 1998;24:345-352.
48. Lou H, Kaur K, Sharma AK, Singal PK. Adriamycin-induced oxidative stress, activation of MAP kinases and apoptosis in isolated cardiomyocytes. Pathophysiology 2006;13:103-109.
49. Westermann D, Rutschow S, Van Linthout S, Linderer A, Bücker-Gärtner C, Sobirey M et al. Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 2006;49:2507-2513.